MIME-Version: 1.0
Content-Type: multipart/related; boundary="----=_NextPart_01D8A520.40BD3D70"

Данный документ является веб-страницей в одном файле, также называемой файлом веб-архива. Если вы видите это сообщение, значит, данный браузер или редактор не поддерживает файлы веб-архива. Загрузите браузер, поддерживающий веб-архивы, например Windows® Internet Explorer®.

------=_NextPart_01D8A520.40BD3D70
Content-Location: file:///C:/680D9C53/UA171110101_9EA3.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1251"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
1">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 14">
<meta name=3DOriginator content=3D"Microsoft Word 14">
<link rel=3DFile-List href=3D"UA171110101_9EA3.files/filelist.xml">
<link rel=3DPreview href=3D"UA171110101_9EA3.files/preview.wmf">
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>1</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Bravada</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>2</o:TotalTime>
  <o:LastPrinted>2021-12-24T08:31:00Z</o:LastPrinted>
  <o:Created>2022-07-31T17:58:00Z</o:Created>
  <o:LastSaved>2022-07-31T17:58:00Z</o:LastSaved>
  <o:Pages>5</o:Pages>
  <o:Words>1921</o:Words>
  <o:Characters>10951</o:Characters>
  <o:Company>SPecialiST RePack</o:Company>
  <o:Lines>91</o:Lines>
  <o:Paragraphs>25</o:Paragraphs>
  <o:CharactersWithSpaces>12847</o:CharactersWithSpaces>
  <o:Version>14.00</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=3DdataStoreItem href=3D"UA171110101_9EA3.files/item0001.xml"
target=3D"UA171110101_9EA3.files/props002.xml">
<link rel=3DthemeData href=3D"UA171110101_9EA3.files/themedata.thmx">
<link rel=3DcolorSchemeMapping
href=3D"UA171110101_9EA3.files/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:HyphenationZone>21</w:HyphenationZone>
  <w:PunctuationKerning/>
  <w:DrawingGridHorizontalSpacing>6 пт</w:DrawingGridHorizontalSpacing>
  <w:DisplayHorizontalDrawingGridEvery>2</w:DisplayHorizontalDrawingGridEve=
ry>
  <w:DisplayVerticalDrawingGridEvery>2</w:DisplayVerticalDrawingGridEvery>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>RU</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:DontUseIndentAsNumberingTabStop/>
   <w:FELineBreak11/>
   <w:WW11IndentRules/>
   <w:DontAutofitConstrainedTables/>
   <w:AutofitLikeWW11/>
   <w:HangulWidthLikeWW11/>
   <w:UseNormalStyleForList/>
   <w:DontVertAlignCellWithSp/>
   <w:DontBreakConstrainedForcedTables/>
   <w:DontVertAlignInTxbx/>
   <w:Word11KerningPairs/>
   <w:CachedColBalance/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val=3D"Cambria Math"/>
   <m:brkBin m:val=3D"before"/>
   <m:brkBinSub m:val=3D"&#45;-"/>
   <m:smallFrac m:val=3D"off"/>
   <m:dispDef/>
   <m:lMargin m:val=3D"0"/>
   <m:rMargin m:val=3D"0"/>
   <m:defJc m:val=3D"centerGroup"/>
   <m:wrapIndent m:val=3D"1440"/>
   <m:intLim m:val=3D"subSup"/>
   <m:naryLim m:val=3D"undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState=3D"false" DefUnhideWhenUsed=3D"true"
  DefSemiHidden=3D"true" DefQFormat=3D"false" DefPriority=3D"99"
  LatentStyleCount=3D"267">
  <w:LsdException Locked=3D"false" Priority=3D"0" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Normal"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"heading 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"35" QFormat=3D"true" Name=3D=
"caption"/>
  <w:LsdException Locked=3D"false" Priority=3D"10" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" Name=3D"Default Paragraph=
 Font"/>
  <w:LsdException Locked=3D"false" Priority=3D"11" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtitle"/>
  <w:LsdException Locked=3D"false" Priority=3D"22" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Strong"/>
  <w:LsdException Locked=3D"false" Priority=3D"20" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"59" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Table Grid"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false" Name=3D"Placeho=
lder Text"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"No Spacing"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false" Name=3D"Revisio=
n"/>
  <w:LsdException Locked=3D"false" Priority=3D"34" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"List Paragraph"/>
  <w:LsdException Locked=3D"false" Priority=3D"29" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"30" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"19" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"21" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"31" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"32" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"33" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Book Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"37" Name=3D"Bibliography"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" QFormat=3D"true" Name=3D=
"TOC Heading"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520092929 1073786111 9 0 415 0;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520084737 -1073683329 41 0 479 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:Calibri;
	mso-fareast-language:EN-US;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Текст примечания Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:Calibri;
	mso-fareast-language:EN-US;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-priority:99;
	mso-style-link:"Верхний колонтитул Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 233.85pt right 467.75pt;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-priority:99;
	mso-style-link:"Нижний колонтитул Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 233.85pt right 467.75pt;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:Calibri;
	mso-fareast-language:EN-US;}
span.MsoCommentReference
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Основной текст 2 Знак";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	line-height:200%;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:UK;}
a:link, span.MsoHyperlink
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-noshow:yes;
	mso-style-priority:99;
	color:purple;
	mso-themecolor:followedhyperlink;
	text-decoration:underline;
	text-underline:single;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"Текст примечания";
	mso-style-link:"Тема примечания Знак";
	mso-style-next:"Текст примечания";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:Calibri;
	mso-fareast-language:EN-US;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Текст выноски Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Segoe UI","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-fareast-language:EN-US;}
span.a
	{mso-style-name:"Верхний колонтитул Знак";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Верхний колонтитул";
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:RU;}
span.2
	{mso-style-name:"Основной текст 2 Знак";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Основной текст 2";
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:RU;}
p.a0, li.a0, div.a0
	{mso-style-name:\00CE\00E1\00FB\00F7\00ED\00FB\00E9;
	mso-style-unhide:no;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	mso-layout-grid-align:none;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-language:EN-US;}
span.hps
	{mso-style-name:hps;
	mso-style-unhide:no;}
span.a1
	{mso-style-name:"Текст примечания Знак";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Текст примечания";
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;}
span.a2
	{mso-style-name:"Тема примечания Знак";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Тема примечания";
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-weight:bold;}
span.a3
	{mso-style-name:"Текст выноски Знак";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Текст выноски";
	mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Segoe UI","sans-serif";
	mso-ascii-font-family:"Segoe UI";
	mso-hansi-font-family:"Segoe UI";
	mso-bidi-font-family:"Segoe UI";}
span.a4
	{mso-style-name:"Нижний колонтитул Знак";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Нижний колонтитул";}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	mso-fareast-font-family:Calibri;}
 /* Page Definitions */
 @page
	{mso-footnote-separator:url("UA171110101_9EA3.files/header.htm") fs;
	mso-footnote-continuation-separator:url("UA171110101_9EA3.files/header.htm=
") fcs;
	mso-endnote-separator:url("UA171110101_9EA3.files/header.htm") es;
	mso-endnote-continuation-separator:url("UA171110101_9EA3.files/header.htm"=
) ecs;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:42.55pt 42.5pt 42.55pt 3.0cm;
	mso-header-margin:35.45pt;
	mso-footer-margin:35.45pt;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 @list l0
	{mso-list-id:1772969144;
	mso-list-template-ids:1815238304;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l0:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l0:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Wingdings;}
@list l0:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Wingdings;}
@list l0:level5
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Wingdings;}
@list l0:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Wingdings;}
@list l0:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Wingdings;}
@list l0:level8
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Wingdings;}
@list l0:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Wingdings;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Обычная таблица";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
table.MsoTableGrid
	{mso-style-name:"Сетка таблицы";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-priority:59;
	mso-style-unhide:no;
	border:solid windowtext 1.0pt;
	mso-border-alt:solid windowtext .5pt;
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-border-insideh:.5pt solid windowtext;
	mso-border-insidev:.5pt solid windowtext;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext=3D"edit">
  <o:idmap v:ext=3D"edit" data=3D"1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=3DRU link=3Dblue vlink=3Dpurple style=3D'tab-interval:35.4pt'>

<div class=3DWordSection1>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><b style=3D=
'mso-bidi-font-weight:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>ІНСТРУКЦІЯ<=
o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><b><span la=
ng=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'>для медичного застосування </=
span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:UK'>лікарського засобу </span></b><b><span lang=3D=
UK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><b><span la=
ng=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></b><=
/p>

<p class=3DMsoNormal style=3D'margin-left:177.0pt;text-align:justify'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:UK'><span style=3D'mso-spacerun:yes'>     
</span>ФАРЛІНЕКС<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-left:177.0pt;text-align:justify'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:UK'><span style=3D'mso-spacerun:yes'>      
</span>FARLYNEX</span></b><b><span lang=3DUK style=3D'mso-bidi-font-size:12=
.0pt;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;=
</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Склад:<o:p>=
</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify;tab-stops:184.3pt'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>діючі речовини: </span></i><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'>с</span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK'>hlorhexidine
digluconate, lidocaine hydrochloride;</span><i style=3D'mso-bidi-font-style=
:normal'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify;mso-la=
yout-grid-align:
none;text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0p=
t;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>1 мл розчину містить х</span><span lang=3DUK style=3D'mso-bidi-font-siz=
e:12.0pt;
mso-ansi-language:UK'>лоргексидину диглюконату 2,00</span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'> мг,</span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK;mso-fareast-languag=
e:
RU'> лідокаїну гідрохлориду 0,50 мг</span><span lang=3DUK style=3D'mso-bidi=
-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>допоміжні
речовини: </span></i><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>етанол 96 %,
гліцерин 85 %, ментол рацемічний, сахарин натрію, кислота лимонна, моногідр=
ат;
вода очищена.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'><span
style=3D'mso-spacerun:yes'> </span><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'>Лікарська форма. </span></b><=
span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>Спрей оромукозний, розчин</sp=
an><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK;mso-farea=
st-language:
RU'>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><i><s=
pan
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU;mso-bidi-font-weight:bold'>Осн=
овні
фізико-хімічні властивості: </span></i><span lang=3DUK style=3D'mso-bidi-fo=
nt-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK'>безб=
арвний
розчин із специфічним запахом.<span style=3D'text-transform:uppercase'><o:p=
></o:p></span></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></b><=
/p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'>Фармакотерапевтична група. <o=
:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><a
href=3D"https://medhub.info/sredstva-primeniaemye-pri-zabolevaniiah-gorla-r=
02a/6ebf9be7"><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
color:windowtext;mso-ansi-language:UK;mso-fareast-language:RU;text-decorati=
on:
none;text-underline:none'>Засоби, що застосовуються при захворюваннях горла=
</span></a><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>. Антисептики.<o:p></o:p></sp=
an></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>Код АТХ R02AA05.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></b><=
/p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Фармакологі=
чні
властивості.<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'>Фармакодинаміка. <o:p></o:p><=
/span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify;mso-pagination:none;mso-hy=
phenate:
none'><span class=3Dhps><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;
mso-ansi-language:UK'>Лідокаїн є місцевим знеболювальним засобом амідного т=
ипу.
Подібно до інших місцевих знеболювальних засобів, лідокаїн знижує генерацію=
 і
провідність нервових імпульсів шляхом уповільнення деполяризації. Це виникає
внаслідок блокування великого транзиторного підвищення у проникності клітин=
ної
мембрани для іонів натрію, який слідує за початковою деполяризацією мембран=
и.
Лідокаїн також знижує проникність іонів калію і натрію до спокійного нейрон=
а.<o:p></o:p></span></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>Хлоргексидин є антисептиком г=
рупи
біс-бігуаніду і дезінфектантом, що чинить бактерицидну або бактеріостатичну=
 дію
щодо широкого спектра грампозитивних і грам-негативних бактерій. Більш
ефективний щодо грампозитивних, ніж грамнегативних бактерій і деяких видів =
<i
style=3D'mso-bidi-font-style:normal'>Pseudomonas</i> і <i style=3D'mso-bidi=
-font-style:
normal'>Proteus, </i>що мають низьку чутливість. Він відносно неактивний що=
до
мікобактерій. Пригнічує деякі віруси і є активним проти деяких грибів.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'>Фармакокінетика. <o:p></o:p><=
/span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify;tab-st=
ops:
36.0pt'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Препарат
застосовують місцево, на слизову оболонку горла. При заковтуванні розчину і=
з слиною
невелика кількість його може потрапляти до шлунка, а також деяка кількість =
може
абсорбуватися зі слизових оболонок рота і горла.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify;tab-st=
ops:
36.0pt'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Лідокаїн до=
бре проникає
через слизові оболонки порожнини рота, шлунково-кишкового тракту і через
пошкоджену шкіру. Абсорбція через непошкоджену шкіру незначна. Досистемний
метаболізм має екстенсивний характер і біодоступність після перорального за=
стосування
становить лише близько 35 %. Після всмоктування лідокаїн швидко проникає у =
всі
тканини тіла. Він проходить через плацентарний і гематоенцефалічний бар'єр.
Приблизно 65 % його зв’язується з білками плазми крові. Період напіввиведен=
ня із
плазми крові становить 1,6 години. Лідокаїн переважно метаболізується у
печінці. Будь-які функціональні зміни у печінці або у печінковому кров’яном=
у руслі
чинять суттєвий вплив на його фармакокінетику і, відповідно, на дозування.
Метаболізм у печінці швидкий. Приблизно 90 % дози деалкілується з утворення=
м моноетилгліцинексилідиду
(MEГЕ) і гліцинексилідиду (ГЕ); обидва метаболіти можуть посилювати
терапевтичний і токсичний ефект лідокаїну. Продукти метаболізму і близько 1=
0 %
лідокаїну у незміненому вигляді екскретуються із сечею.<o:p></o:p></span></=
p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>Хлоргексидин практично не всмоктується через мембр=
ани
слизових оболонок, непошкодженої шкіри і шлунково-кишкового тракту. Він лише
мінімально метаболізується печінкою і виділяється із жовчю. Виділення із се=
чею
дуже незначне.</span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-ansi-language:
UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;=
</o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Клінічні
характеристики.<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Показання.<=
o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK;mso-farea=
st-language:
RU'>Симптоматичне лікування болю та подразнення при запаленні горла.</span>=
<span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'>Як додаткову терапію можна застосовувати при комплекс=
ному
лікуванні бактеріальних інфекцій горла, що супроводжуються пропасницею.</sp=
an><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;=
</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Протипоказа=
ння.</span></i></b><b><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'> <o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK'>Гіпе=
рчутливість
до </span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;letter-spacing=
:-.15pt;
mso-ansi-language:UK;mso-fareast-language:UK'>хлоргексидину, лідокаїну та і=
нших
місцевознеболювальних засобів амідного типу</span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK'> або до будь-якого іншого компонента препарату.<b
style=3D'mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;=
</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Взаємодія з
іншими лікарськими засобами та інші види взаємодій.<o:p></o:p></span></i></=
b></p>

<p class=3DMsoNormal style=3D'margin-bottom:4.0pt;text-align:justify'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK'>Хлор=
гексидин</span></i><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'>. Немає даних про взаємодію хлоргексидину з іншими
лікарськими засобами. <i style=3D'mso-bidi-font-style:normal'>Лідокаїн</i>.=
 Взаємодія
інших лікарських засобів з лідокаїном теоретично можлива, але такі взаємоді=
ї будуть
клінічно незначущими при місцевому застосуванні препарату ФАРЛІНЕКС. Одноча=
сне застосування
із засобами, що знижують печінковий кровотік (наприклад, пропранолол,
циметидин), може призвести до зниження кліренсу лідокаїну. Довготривале
застосування із засобами, що метаболізіуються з допомогою мікросомальних ен=
зимів,
(наприклад фенітоїн, барбітурати), може потребувати зміни дозування лідокаї=
ну. Лідокаїн
посилює дію бета- блокаторів та інших антиаритмічних засобів (наприклад
мексилетину). Лідокаїн є слабким інгібітором псевдохолінестерази і може
подовжувати дію суксаметонію. Гіпокаліємія, спричинена ацетазоламідом,
петльовими і тіазидними діуретиками, може знижувати дію лідокаїну. Під час =
застосування
препарату ФАРЛІНЕКС пацієнтам не слід застосовувати одночасно інші місцеві
антисептичні перепрати для дезінфекції рота та/або горла.<o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></b><=
/p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Особливості
застосування.</span></i></b><b><span lang=3DUK style=3D'mso-bidi-font-size:=
12.0pt;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'> <o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:4.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'>Застосовувати препарат ФАРЛІНЕКС слід суворо за
необхідності, симптоматично до полегшення болю або подразнення. Препарат не
призначений для тривалого, постійного або частого застосування.<o:p></o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-bottom:4.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'>Якщо після 3–4 днів від початку лікування стан пацієн=
та
не поліпшується або навіть стає гіршим, слід звернутися до лікаря для
визначення подальшого лікування.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:4.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'>Препарат ФАРЛІНЕКС </span><span lang=3DUK style=3D'ms=
o-bidi-font-size:
12.0pt;mso-ansi-language:UK'>містить хлоргексидин. Відомо, що хлоргексидин
спричиняє гіперчутливість, включаючи генералізовані алергічні реакції та
анафілактичний шок. Частота проявів таких реакцій гіперчутливості до
хлоргексидину невідома, доступні<span style=3D'mso-spacerun:yes'> 
</span>літературні дані свідчать, що вони зустрічаються рідко. Тому</span><=
span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'> препарат ФАРЛІНЕКС протипоказаний особам із тяжкими
алергічними реакціями на хлоргексидин або його сполуки <span
style=3D'mso-spacerun:yes'> </span>в анамнезі.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:4.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'>Не призначати пацієнтам, які мають труднощі при ковта=
нні.
Хворим із тяжкими інфекціями горла або запаленням горла, що тривають більше=
 2
днів або супроводжуються сильною пропасницею, головним болем, нудотою або
блюванням, ФАРЛІНЕКС можна застосовувати тільки за рекомендацією лікаря.<o:=
p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:4.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'>При використанні місцевих знеболювальних засобів для =
<span
style=3D'mso-spacerun:yes'> </span>рота або горла розвиток місцевої анестез=
ії може
погіршити функцію ковтання і, таким чином, підвищити небезпеку аспірації. У
зв’язку з цим пацієнтів слід попереджати про те, що протягом 1 години після
застосування засобу ФАРЛІНЕКС не рекомендується вживати їжу та/або напої.
Необхідно також уникати чищення зубів і жування гумки на період, коли зона =
рота
та/або горла знеболені.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:4.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'>Слід уникати потрапляння розчину на шкіру, в очі та в=
уха.
Якщо це випадково сталось, очі необхідно промити чистою водою або розчином =
для
промивання очей і утримувати повіки відкритими принаймні протягом 15 хвилин=
.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:4.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'>ФАРЛІНЕКС містить етанол 96 %. Кожен мілілітр розчину
містить 350 мг етанолу, тобто одне натискання насоса вивільняє 0,14 мл розч=
ину,
що відповідає 49 мг етанолу. Вміст етанолу у найбільшій дозі при одноразово=
му
застосуванні препарату для дорослих і дітей віком від 12 років становить 19=
6 мг.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'>ФАРЛІНЕКС спрей не містить цукру і тому його можна за=
стосовувати
пацієнтам, хворим на діабет.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:1.1pt;text-align:justify;mso-lay=
out-grid-align:
none;text-autospace:none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0p=
t;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK'><span
style=3D'mso-spacerun:yes'> </span></span><b><i style=3D'mso-bidi-font-styl=
e:normal'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify;tab-stops:35.4pt center 23=
3.85pt right 467.75pt'><b
style=3D'mso-bidi-font-weight:normal'><i style=3D'mso-bidi-font-style:norma=
l'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>Застосування у період вагітно=
сті
або годування груддю.<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK'>Вагітність.<b style=3D'mso-bidi-fon=
t-weight:
normal'><o:p></o:p></b></span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK'>Нема=
є достатніх
даних щодо безпеки при місцевому застосуванні лідокаїну і хлоргексидину ваг=
ітним
жінкам. Тому ФАРЛІНЕКС спрей можна застосовувати у період вагітності тільки=
 за
рекомендацією лікаря, якщо очікувана користь переважатиме ризик для матері і
плода.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Годування
груддю.<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>Лідокаїн проникає у грудне молоко, але в дуже
незначних кількостях, тому загалом не передбачається ризик впливу на немовл=
я при
застосуванні препарату у терапевтичних дозах.</span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK'> ФАРЛІНЕКС спрей можна застосовувати у період годуван=
ня
груддю за рекомендацією лікаря.</span><b style=3D'mso-bidi-font-weight:norm=
al'><i><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><i><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-f=
ont-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;=
</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><i><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-f=
ont-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Здатність
впливати на швидкість реакції при керуванні автотранспортом або<span
style=3D'mso-spacerun:yes'>  </span>іншими механізмами.<o:p></o:p></span></=
i></b></p>

<p class=3DMsoNormal><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-ansi-language:
UK'>Дані щодо впливу відсутні.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU;mso-bidi-fon=
t-weight:
bold'><span style=3D'mso-spacerun:yes'> </span><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><b
style=3D'mso-bidi-font-weight:normal'><i style=3D'mso-bidi-font-style:norma=
l'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>Спосіб застосування та дози.<=
o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-ansi-language:UK;mso-fareast-language:RU'>Підготовка до першого
застосування.<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK;mso-farea=
st-language:
RU'>Засіб призначений для індивідуального користування.<o:p></o:p></span></=
p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>Перед першим використанням</s=
pan><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK;mso-farea=
st-language:
RU'> слід зняти пластикову кришечку із </span><span lang=3DUK style=3D'mso-=
bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>насоса-розпилювача, надіти</span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK;mso-fareast-languag=
e:
RU'> аплікатор на </span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>насос-розпилювач і злегка притиснути.</span><span lang=3DUK style=3D'ms=
o-bidi-font-size:
12.0pt;mso-ansi-language:UK;mso-fareast-language:RU'> Аплікатором можна рух=
ати
вбік, і повертати вгору під прямим кутом до флакона, що забезпечує правильне
застосування спрею. Перед першим застосуванням необхідно спочатку декілька
разів натиснути на </span><span lang=3DUK style=3D'mso-bidi-font-size:12.0p=
t;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>насос-розпилювач до утворення рівномірної хмарки спрею.</span><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK;mso-farea=
st-language:
RU'> Широко розкривши рот, спрямувати аплікатор у горло і натиснути </span>=
<span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>насос-розпилювач стільки разі=
в, як
це вказано в дозуванні засобу. Протягом процедури впорскування препарату
необхідно</span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-ansi=
-language:
UK;mso-fareast-language:RU'> затримати дихання. Не ковтати. Після застосува=
ння
засобу аплікатор повертати вниз для блокування </span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'>насоса-розпилювача з метою
уникнення розпилення спрею при випадковому натисканні</span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK;mso-fareast-languag=
e:
RU'>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-ansi-language:UK;mso-fareast-language:RU'>Дозування. </span></i>=
<span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK;mso-farea=
st-language:
RU'>Одне натискання вивільняє 0,14 мл розчину, що містить 0,28 мг хлоргекси=
дину
диглюконату і 0,07 мг лідокаїну гідрохлориду.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-ansi-language:UK;mso-fareast-language:RU'>Дорослі та діти віком =
від
12 років.<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'>Рекомендована разова доза становить 2–4 упорскування.
Кількість застосувань препарату становить 6–10 разів на добу.<o:p></o:p></s=
pan></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;=
</o:p></span></i></b></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><i style=3D'm=
so-bidi-font-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Діти. </spa=
n></i></b><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>Не застосовувати </span><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'><span style=3D'mso-spacerun:yes'> </span>дітям віком =
до 12
років.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;mso-pagination:none;mso-la=
yout-grid-align:
none'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-f=
amily:
"Times New Roman";mso-ansi-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;=
</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;=
</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;=
</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Передозуван=
ня.</span></i></b><b><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'> <o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>Ознаки і симптоми. </span></i><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'>Застосування місцевих знеболю=
вальних
препаратів може погіршувати функцію ковтання і таким чином спричиняти небез=
пеку
аспірації їжі та напоїв у дихальні шляхи. Передозування препаратом </span><=
span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'>ФАРЛІНЕКС спрей (10 мл і більше) може стати причиною
виникнення ризику дуже сильної місцевої анестезії у ділянці голосової щілин=
и і,
як наслідок, значного погіршення функції ковтання.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>Надзвичайно високі концентрац=
ії
лідокаїну у крові можуть спричинити вплив на центральну нервову та/або
серцево-судинну системи. Ранніми проявами впливу на ЦНС може бути нервозніс=
ть,
запаморочення, шум у вухах, ністагм, занепокоєння, збудження, парестезії,
помутніння зору, нудота, блювання і тремор, які можуть перерости у медулярну
депресію, тонічні або клонічні судоми. Пригнічувальний вплив на серцево-суд=
инну
систему може проявлятися гіпотензією, послабленням роботи міокарда,
брадикардією і навіть зупинкою серця. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>Біодоступність лідокаїну низь=
ка, але
при заковтуванні </span><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK'>у кількості,
еквівалентній 0,5 г і більше</span><span lang=3DUK style=3D'mso-bidi-font-s=
ize:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'> цього може бути достатньо для проявів токсичності.
Були повідомлення про токсичний вплив на ЦНС, напади і летальний випадок пі=
сля
прийому всередину місцевознеболювальних засобів. Що стосується препарату </=
span><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'>ФАРЛІНЕКС спрей, то для отримання дози, при якій можл=
иво
було б очікувати токсичні прояви, необхідно проковтнути більше 1000 мл преп=
арату.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'>Прояви системної токсичності хлоргексидину відзначают=
ься рідко.
Головним наслідком потрапляння всередину надмірних доз може бути подразнення
слизових оболонок.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK'>Ліку=
вання.
</span></i><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-f=
ont-family:
"Times New Roman";mso-ansi-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK'>Лікування передозування лідокаїном симптоматичне і
полягає у забезпеченні належної вентиляції легень і зупинення судомів. У ра=
зі
необхідності вентиляцію киснем забезпечують за допомогою допоміжного або
контрольованого дихання. У випадку появи судом застосовувати тіопентал,
діазепам або сукцинілхолін. Оскільки сукцинілхолін може спричинити зупинку
дихання, його слід <span style=3D'mso-spacerun:yes'> </span>використовувати=
 лише
у випадку, якщо лікар має можливість виконати ендотрахеальну інтубацію і ко=
нтролювати
стан повністю<b style=3D'mso-bidi-font-weight:normal'><u> </u></b>знерухомл=
еного
пацієнта. У разі фібриляції шлуночків або зупинки серця слід проводити
ефективну серцево-судинну реанімацію. Якомога швидше необхідно застосувати =
<span
style=3D'mso-spacerun:yes'> </span>адреналін (при відсутності ефекту – у по=
вторних
дозах) і натрію бікарбонат.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;=
</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><i style=3D'mso-bidi-f=
ont-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Побічні
реакції.</span></i></b><b><span lang=3DUK style=3D'mso-bidi-font-size:12.0p=
t;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'> <o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:3.0pt;text-align:justify'><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU;mso-bidi-font-weight:bold'>При=
 застосуванні
у рекомендованих дозах зазвичай препарат </span><span lang=3DUK style=3D'ms=
o-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>добре переноситься, і </span><span class=3Dhps><sp=
an
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK'>не було
повідомлень<span style=3D'mso-spacerun:yes'>  </span>про небажані ефекти пі=
д час
нетривалого місцевого використання.<o:p></o:p></span></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>Але у надзвичайно рідких випадках можуть виникнути=
 побічні
реакції.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>З боку шкір=
и та
підшкірних тканин:</span></i><span lang=3DUK style=3D'font-size:11.0pt;font=
-family:
"Arial","sans-serif";mso-ansi-language:UK'> </span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK'>алергічні шкірні
реакції, такі як дерматит, свербіж,<br>
еритема, екзема, висип, кропив'янка, подразнення шкіри та пухирі.<o:p></o:p=
></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-ansi-language:UK'>Оскільки препарат містить у складі діючі речов=
ини
лідокаїн та хлоргексидин, необхідно враховувати можливі небажані реакції, з=
умовлені
кожним із цих компонентів.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Лідокаїн</s=
pan></i><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>З боку імун=
ної
системи: </span></i><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-=
fareast-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>гіперчутлив=
ість,
включаючи набряк із незначним ускладненням дихання, генералізований висип.<=
o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Хлоргексиди=
н.<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>З боку імун=
ної
системи: </span></i><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-=
fareast-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>гіперчутлив=
ість,
включаючи реакцію з боку шкіри; анафілактичний шок.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><i style=3D'mso-bidi-font=
-style:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font=
-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>З боку орга=
нів
шлунково-кишкового тракту:</span></i><span lang=3DUK style=3D'mso-bidi-font=
-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'> </span><span class=3Dhps><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK'>зміна кольору зубі=
в і
язика (інколи може знадобитись професійна допомога стоматолога), короткочас=
не порушення
смаку, відчуття печіння язика, інколи набряк привушних слинних залоз. Ці яв=
ища
не довготривалі і зникають після припинення<span style=3D'mso-spacerun:yes'=
> 
</span>застосування хлоргексидину. <o:p></o:p></span></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK'><o:p=
>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>Медичних працівників, пацієнтів, фармацевтів проси=
мо
повідомляти про будь-яку підозру на наявність побічних реакцій або відсутні=
сть
терапевтичного ефекту за електронною адресою представництва Босналек д.д.: =
</span><a
href=3D"mailto:office@bosnalijek.com.ua"><span lang=3DUK style=3D'mso-bidi-=
font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";color:windowtext;mso-ansi-=
language:
UK;mso-fareast-language:RU'>office@bosnalijek.com.ua</span></a><span lang=
=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU;mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span=
></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'ms=
o-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>Термін придатності.<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>2 роки.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></b><=
/p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'>Умови зберігання. <o:p></o:p>=
</span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>Зберігати при температурі не вище 25 </span><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;font-family:Symbol;mso-ascii-f=
ont-family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-hansi-font-=
family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU;mso-char-typ=
e:
symbol;mso-symbol-font-family:Symbol'><span style=3D'mso-char-type:symbol;
mso-symbol-font-family:Symbol'>°</span></span><span lang=3DUK style=3D'mso-=
bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>С. </span><span lang=3DUK style=3D'mso-bidi-font-s=
ize:
12.0pt;mso-ansi-language:UK'>Не заморожувати.</span><b><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>Зберігати у недоступному для дітей місці.<b><o:p><=
/o:p></b></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></b><=
/p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'>Упаковка. <o:p></o:p></span><=
/b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>По 30 мл у </span><span lang=3DUK style=3D'mso-bid=
i-font-size:
12.0pt;mso-ansi-language:UK'>флаконі</span><span lang=3DUK style=3D'mso-bid=
i-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>, по 1 флакону </span><span lang=3DUK style=3D'mso=
-bidi-font-size:
12.0pt;mso-ansi-language:UK'>з насосом-розпилювачем та аплікатором</span><s=
pan
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'> в картонній коробці.<o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></b><=
/p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'>Категорія відпуску. <o:p></o:=
p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU;mso-bidi-font-weight:bold'>Без</span><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'> рецепта.<o:p></o:p></span></=
p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU;mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span>=
</p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:UK'>Виробник.</span></b><b><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'> <o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>Босналек д.д.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b><span lang=3DUK
style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times New Roman=
";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></b><=
/p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:UK'>Місцезнаходження
виробника та адреса місця провадження його діяльності</span></b><b><span
lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:"Times=
 New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>. <o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>71000, Сараєво, Юкічева, 53, Боснія і Герцеговина.=
<o:p></o:p></span></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p><=
/span></b></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK'>Заявник. <o:p></o:=
p></span></b></p>

<p class=3DMsoNormal><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso=
-fareast-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Босналек д.=
д.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:UK'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DUK style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:UK'>Місцезнаходження
заявника та/або представника заявника.<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'text-align:justify'><span lang=3DUK style=3D'=
mso-bidi-font-size:
12.0pt;mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;
mso-fareast-language:RU'>71000, Сараєво, Юкічева, 53, Боснія і Герцеговина.=
<o:p></o:p></span></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p><=
/span></b></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:UK'><o:p>&nbsp;</o:p><=
/span></b></p>

</div>

</body>

</html>

------=_NextPart_01D8A520.40BD3D70
Content-Location: file:///C:/680D9C53/UA171110101_9EA3.files/preview.wmf
Content-Transfer-Encoding: base64
Content-Type: image/x-wmf
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------=_NextPart_01D8A520.40BD3D70
Content-Location: file:///C:/680D9C53/UA171110101_9EA3.files/item0001.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<b:Sources SelectedStyle=3D"\APA.XSL" StyleName=3D"APA" xmlns:b=3D"http://s=
chemas.openxmlformats.org/officeDocument/2006/bibliography" xmlns=3D"http:/=
/schemas.openxmlformats.org/officeDocument/2006/bibliography"></b:Sources>

------=_NextPart_01D8A520.40BD3D70
Content-Location: file:///C:/680D9C53/UA171110101_9EA3.files/props002.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<ds:datastoreItem ds:itemID=3D"{AB2A9AE8-D6DF-40CA-988D-BDBF4330DF55}" xmln=
s:ds=3D"http://schemas.openxmlformats.org/officeDocument/2006/customXml"><d=
s:schemaRefs><ds:schemaRef ds:uri=3D"http://schemas.openxmlformats.org/offi=
ceDocument/2006/bibliography"/></ds:schemaRefs></ds:datastoreItem>
------=_NextPart_01D8A520.40BD3D70
Content-Location: file:///C:/680D9C53/UA171110101_9EA3.files/themedata.thmx
Content-Transfer-Encoding: base64
Content-Type: application/vnd.ms-officetheme
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------=_NextPart_01D8A520.40BD3D70
Content-Location: file:///C:/680D9C53/UA171110101_9EA3.files/colorschememapping.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"yes"?>
<a:clrMap xmlns:a=3D"http://schemas.openxmlformats.org/drawingml/2006/main"=
 bg1=3D"lt1" tx1=3D"dk1" bg2=3D"lt2" tx2=3D"dk2" accent1=3D"accent1" accent=
2=3D"accent2" accent3=3D"accent3" accent4=3D"accent4" accent5=3D"accent5" a=
ccent6=3D"accent6" hlink=3D"hlink" folHlink=3D"folHlink"/>
------=_NextPart_01D8A520.40BD3D70
Content-Location: file:///C:/680D9C53/UA171110101_9EA3.files/header.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1251"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
1">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 14">
<meta name=3DOriginator content=3D"Microsoft Word 14">
<link id=3DMain-File rel=3DMain-File href=3D"../UA171110101_9EA3.htm">
<![if IE]>
<base href=3D"file:///C:\680D9C53\UA171110101_9EA3.files\header.htm"
id=3D"webarch_temp_base_tag">
<![endif]>
</head>

<body lang=3DRU link=3Dblue vlink=3Dpurple>

<div style=3D'mso-element:footnote-separator' id=3Dfs>

<p class=3DMsoNormal><span style=3D'mso-special-character:footnote-separato=
r'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></p>

</div>

<div style=3D'mso-element:footnote-continuation-separator' id=3Dfcs>

<p class=3DMsoNormal><span style=3D'mso-special-character:footnote-continua=
tion-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></p>

</div>

<div style=3D'mso-element:endnote-separator' id=3Des>

<p class=3DMsoNormal><span style=3D'mso-special-character:footnote-separato=
r'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></p>

</div>

<div style=3D'mso-element:endnote-continuation-separator' id=3Decs>

<p class=3DMsoNormal><span style=3D'mso-special-character:footnote-continua=
tion-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></p>

</div>

</body>

</html>

------=_NextPart_01D8A520.40BD3D70
Content-Location: file:///C:/680D9C53/UA171110101_9EA3.files/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"

<xml xmlns:o=3D"urn:schemas-microsoft-com:office:office">
 <o:MainFile HRef=3D"../UA171110101_9EA3.htm"/>
 <o:File HRef=3D"preview.wmf"/>
 <o:File HRef=3D"item0001.xml"/>
 <o:File HRef=3D"props002.xml"/>
 <o:File HRef=3D"themedata.thmx"/>
 <o:File HRef=3D"colorschememapping.xml"/>
 <o:File HRef=3D"header.htm"/>
 <o:File HRef=3D"filelist.xml"/>
</xml>
------=_NextPart_01D8A520.40BD3D70--
